CoChat

B cell depletion therapy exacerbates murine primary biliary cirrhosis

Open access
Dhirapong, Amy, Lleo, Ana, Yang, Guo-Xiang, Tsuneyama, Koichi, Dunn, Robert, Kehry, Marilyn, Packard, Thomas A., Cambier, John C., Liu, Fu-Tong, Lindor, Keith, Coppel, Ross L., Ansari, Aftab A., Gershwin, M. Eric · 2011 · Hepatology
Cited by 70

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

UNLABELLED: Primary biliary cirrhosis (PBC) is considered a model autoimmune disease due to the clinical homogeneity of patients and the classic hallmark of antimitochondrial antibodies (AMAs). Indeed, the presence of AMAs represents the most highly directed and specific autoantibody in autoimmune diseases. However, the contribution of B cells to the pathogenesis of PBC is unclear. Therefore, although AMAs appear to interact with the biliary cell apotope and contribute to biliary pathology, there is no correlation of disease severity and titer of AMAs. The recent development of well-characterized monoclonal antibodies specific for the B cell populations, anti-CD20 and anti-CD79, and the development of a well-defined xenobiotic-induced model of autoimmune cholangitis prompted us to use these reagents and the model to address the contribution of B cells in the pathogenesis of murine PBC. Prior to the induction of autoimmune cholangitis, mice were treated with either anti-CD20, anti-CD79, or isotype-matched control monoclonal antibody and followed for B cell development, the appearance of AMAs, liver pathology, and cytokine production. Results of the studies reported herein show that the in vivo depletion of B cells using either anti-CD20 or anti-CD79 led to the development of a more severe form of cholangitis than observed in control mice, which is in contrast with results from several other autoimmune models that have documented an important therapeutic role of B cell-specific depletion. Anti-CD20/CD79-treated mice had increased liver T cell infiltrates and higher levels of proinflammatory cytokines. CONCLUSION: Our results reflect a novel disease-protective role of B cells in PBC and suggest that B cell depletion therapy in humans with PBC should be approached with caution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.24044

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 70

Metadata

Authors
Dhirapong, A., Lleo, A., Yang, G.-X., Tsuneyama, K., Dunn, R., Kehry, M., Packard, T. A., Cambier, J. C., Liu, F.-T., Lindor, K., Coppel, R. L., Ansari, A. A., & Gershwin, M. E.
Venue
Hepatology
Published
2010-12-28
Volume
53
Issue
2
Pages
527-535
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1988536734
Cited by
70
References
10
FWCI
4.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: B cell depletion therapy exacerbates murine primary biliary cirrhosis. https://app.cochat.ai/papers/10.1002/hep.24044
The paper
Dhirapong, A., Lleo, A., Yang, G.-X., Tsuneyama, K., Dunn, R., Kehry, M., Packard, T. A., Cambier, J. C., Liu, F.-T., Lindor, K., Coppel, R. L., Ansari, A. A., & Gershwin, M. E. (2011). B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology. https://doi.org/10.1002/hep.24044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.